MH & Associates Securities Management Corp ADV Invests $3.10 Million in Biogen Inc. $BIIB

MH & Associates Securities Management Corp ADV purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 17,598 shares of the biotechnology company’s stock, valued at approximately $3,097,000. Biogen comprises 2.5% of MH & Associates Securities Management Corp ADV’s holdings, making the stock its 18th biggest position.

Several other institutional investors have also modified their holdings of BIIB. Empowered Funds LLC raised its position in shares of Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after buying an additional 2,777 shares during the period. Focus Partners Wealth raised its position in shares of Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of Biogen during the 2nd quarter valued at approximately $216,000. CW Advisors LLC raised its position in shares of Biogen by 35.4% during the 2nd quarter. CW Advisors LLC now owns 4,106 shares of the biotechnology company’s stock valued at $516,000 after buying an additional 1,073 shares during the period. Finally, EverSource Wealth Advisors LLC raised its position in shares of Biogen by 102.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,004 shares of the biotechnology company’s stock valued at $252,000 after buying an additional 1,012 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a multi?target collaboration with Alloy Therapeutics to use Alloy’s AntiClastic™ antisense oligonucleotide (ASO) platform, giving Biogen broad access to RNA?targeting discovery tools and accelerating its antisense pipeline — a clear pipeline/development positive that supports longer?term growth prospects. Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen
• Positive Sentiment: Analyst commentary and coverage pieces highlight Biogen’s strong history of quarterly earnings surprises and argue the company has the setup to beat estimates again — sentiment that tends to support short?term buying ahead of results. Why Biogen (BIIB) Could Beat Earnings Estimates Again
• Neutral Sentiment: Healthcare peers were softer in recent trading sessions, which can weigh on biotech names broadly even when company?specific news is positive; this is a market/sector headwind rather than a Biogen?specific problem. Sector Update: Health Care Stocks Softer Late Afternoon
• Negative Sentiment: RBC lowered its price target on BIIB from $233 to $213 while maintaining an Outperform rating — a downgrade to the target that could temper upside from some investors despite the continued positive rating. RBC Capital Adjusts Biogen Price Target
• Negative Sentiment: Commentary (The Motley Fool) notes Biogen’s first?quarter operating expenses came in higher than some expected, which caused a recent pullback — higher near?term spending could pressure margins and create volatility around upcoming results. Why Biogen Stock Got Mashed on Monday

Biogen Stock Up 2.4%

Shares of NASDAQ:BIIB opened at $179.90 on Thursday. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $202.41. The firm’s 50-day moving average is $186.71 and its two-hundred day moving average is $172.21. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The firm has a market capitalization of $26.40 billion, a PE ratio of 20.42, a price-to-earnings-growth ratio of 2.37 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the prior year, the company earned $3.44 earnings per share. The company’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts predict that Biogen Inc. will post 15.83 EPS for the current year.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.18% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. BMO Capital Markets lifted their price target on shares of Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a research report on Friday, February 6th. Guggenheim boosted their price objective on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a report on Monday, February 9th. Canaccord Genuity Group boosted their price objective on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Finally, Oppenheimer boosted their price objective on shares of Biogen from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, April 1st. Twelve research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Biogen currently has a consensus rating of “Hold” and an average price target of $207.54.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.